SSA
ESLA icon

Schonfeld Strategic Advisors’s Estrella Immunopharma ESLA Stock Holding History

Schonfeld Strategic Advisors’s Portfolio ESLA Stock Details ESLA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q3 		– Sell
-11,277
Closed -$113K – 3025
2022
Q2 		$113K Hold
11,277
– – ﹤0.01% 2101
2022
Q1 		$113K Sell
11,277
-55,687
-83% -$555K ﹤0.01% 2195
2021
Q4 		$664K Buy
66,964
+46,964
+235% +$465K 0.01% 1131
2021
Q3 		$198K Buy
+20,000
New +$197K ﹤0.01% 1774

Other funds holding ESLA

KIM
Karpus Investment Management Pittsford, New York $3.21B AUM 6.83% 1-Year Est. Return
ASM
ATW SPAC Management New York $79.2M AUM 10.67% 1-Year Est. Return
BFM
Boothbay Fund Management New York $7.71B AUM 106.31% 1-Year Est. Return
HHGC
Hunting Hill Global Capital New York $129M AUM 17.34% 1-Year Est. Return
CSS
Cubist Systematic Strategies Stamford, Connecticut $21B AUM 21.48% 1-Year Est. Return
Nomura Holdings
Nomura Holdings Tokyo, Japan $37.7B AUM 34.44% 1-Year Est. Return
CH
CVI Holdings Wilmington, Delaware $116M AUM 5.68% 1-Year Est. Return
Hudson Bay Capital Management
Hudson Bay Capital Management Stamford, Connecticut $29B AUM 30.2% 1-Year Est. Return
RCM
Radcliffe Capital Management Bala Cynwyd, Pennsylvania $1.33B AUM 1.18% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

Schonfeld Strategic Advisors's ESLA Position: Q3 2022 in Review

Schonfeld Strategic Advisors sold out of Estrella Immunopharma (ESLA) in Q3 2022, closing a stake of 11,277 shares — an estimated $113K sold.

Schonfeld Strategic Advisors first reported a position in ESLA in Q3 2021 and held it in 4 quarters. The position peaked at $664K in Q4 2021. 23 funds tracked by Wall St. Rank hold ESLA as of Q3 2022.

  • Schonfeld Strategic Advisors reported no remaining Estrella Immunopharma position as of Q3 2022 after selling out during the quarter.
  • Schonfeld Strategic Advisors sold 11,277 Estrella Immunopharma shares in Q3 2022, an estimated $113K.
  • Schonfeld Strategic Advisors first reported a position in Estrella Immunopharma in Q3 2021 and held it in 4 quarters.
  • Schonfeld Strategic Advisors's Estrella Immunopharma position peaked at $664K in Q4 2021.
  • 23 funds tracked by Wall St. Rank held Estrella Immunopharma as of Q3 2022.

Based on Schonfeld Strategic Advisors's 13F filing for Q3 2022, filed 14 Nov 2022.